Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial

Lipid-Lowering Drugs

Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry

J Am Heart Assoc.

Xian Y, Navar AM, Li S, Li Z, Robinson J, Virani SS, Louie MJ, Koren A, Goldberg A, Roger VL, Wilson PWF, Peterson ED, Wang TY

doi: 10.1161/JAHA.119.013229.

Atrial FibrillationHeart, Artery and Coronary DiseasesThrombosis and Stroke

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.

J Am Heart Assoc.

Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, Alexander JH, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS

doi: 10.1161/JAHA.116.004699.

Heart, Artery and Coronary Diseases

Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2°P-TIMI 50 Trial

Eur Heart J Acute Cardiovasc Care.

Xu H, Bonaca MP, Goodrich E, Scirica BM, Morrow DA

doi: 10.1177/2048872619883354.

Poor attainment of lipid targets in patients with symptomatic peripheral artery disease

doi: 10.1016/j.jacl.2018.02.013.

Heart, Artery and Coronary DiseasesMyocardial InfarctionThrombosis and Stroke

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Lancet.

Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators

doi: 10.1016/S0140-

Heart, Artery and Coronary Diseases

Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial

Am Heart J.

Ward R, Huang Z, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Vemulapalli S, Povsic TJ, Mehta R, Hiatt WR, Patel MR, Jones WS

doi: 10.1016/j.ahj.2019.11.007.

Heart, Artery and Coronary DiseasesMyocardial Infarction

Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial

JAMA Cardiol.

Olivier CB, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW

doi: 10.1001/jamacardio.

Atrial Fibrillation

The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials

Eur Heart J Acute Cardiovasc Care.

Zelniker TA, Ruff CT, Antman EM, Giugliano RP

doi: 10.1177/2048872618796990.

RECOMMENDED

Cardiovascular Risk and Diseases

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Atherosclerosis

Belch JJF, Brodmann M, Baumgartner I, Binder CJ, Casula M, Heiss C, Kahan T, Parini P, Poredos P, Catapano AL, Tokgözoğlu L

doi: 10.1016/j.atherosclerosis.2021.09.022

Related content